Home > Boards > US OTC > Medical - Equipment > GeneSYS ID Inc. (GNID)

GNID CSO and Chief Counsel's poor Attempt to

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
MDRESEARCH Member Profile
 
Followed By 53
Posts 11,598
Boards Moderated 0
Alias Born 11/26/14
160x600 placeholder
MDRESEARCH   Tuesday, 03/27/18 05:32:32 PM
Re: Toxic Avenger post# 32366
Post # of 32391 
GNID CSO and Chief Counsel's poor Attempt to "Cloak" his involvement in GNID Failure, and a Pitiful attempt to "Save Face" with Business Associates and his Piers in Public Corporations. GNID Shareholders are well aware of the last recorded conversion price...

On September 26, 2016, Crownbridge elected to convert $2,473 of the principal amount of note issued on January 12, 2016. The Company issued to Crownbridge 687,000 shares of Company stock.
.00359

AS a CEO of Private Companies and an LLC with Members, I have Learned "ARROGANCE" and the Lack of Communication to Shareholders or Members, will eventually come back to bite you in the Arse.

CEO Yarde and Mark Basile former CSO and Chief Counsel have a long enough RESUME of FAILURE, that should keep them out of any other Publicly traded Company, as Internet provides Great DD.

Case in Point CEO and attempt at Director in Petrone.

Lesson Learned, "GNID" should have left it Right, as we say out here...

The Problem: FAILURE by a CEO in PENNYLAND, is not only an Acceptable Practice, it REWARDS a CEO... It's much EASIER for CEO to make money selling Company shares, than Build a Company.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist